Evidence map›Paper›PMID 41732343›Full record

ArticleThe World Allergy Organization journal2026

Efficacy and safety of olopatadine-mometasone combination nasal spray for the treatment of seasonal allergic rhinitis.

Yutong Sima, Xueyan Wang, Tao Zhang, Zhiwei Cao, Wei Chen, Fang Quan, Xiaoyong Ren, Yi Yang, Shiping Bao, Lifeng Xie and 16 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The World Allergy Organization journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

26 authors.

Yutong SimaDepartment of Otorhinolaryngology Head and Neck Surgery, Beijing Tongren Hospital, Capital Medical University, Beijing, China.
Xueyan WangAllergy Centre, Beijing Shijitan Hospital, Capital Medical University, Beijing, China.
Tao ZhangDepartment of Otorhinolaryngology Head and Neck Surgery, Tianjin Union Medical Center, The First Affiliated Hospital of Nankai University, Tianjin, China.
Zhiwei CaoDepartment of Otorhinolaryngology Head and Neck Surgery, Shengjing Hospital of China Medical University, Shenyang, Liaoning Province, China.
Wei ChenDepartment of Otorhinolaryngology, Central Hospital of Wuhan, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei Province, China.
Fang QuanDepartment of Otorhinolaryngology Head and Neck Surgery, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi Province, China.
Xiaoyong RenDepartment of Otorhinolaryngology Head and Neck Surgery, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi Province, China.
Yi YangDepartment of Otorhinolaryngology, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, China.
Shiping BaoDepartment of Otorhinolaryngology Head and Neck Surgery, Beijing Youan Hospital, Capital Medical University, Beijing, China.
Lifeng XieDepartment of Otorhinolaryngology Head and Neck Surgery, Peking University Third Hospital, Beijing, China.
Changqing ZhaoDepartment of Otorhinolaryngology Head and Neck Surgery, Second Hospital of Shanxi Medical University, Taiyuan, Shanxi Province, China.
Qinna ZhangDepartment of Otorhinolaryngology Head and Neck Surgery, First Hospital of Shanxi Medical University, Taiyuan, Shanxi Province, China.
Zhimin XingDepartment of Otolaryngology Head and Neck Surgery, Peking University People's Hospital, Beijing, China.
Huifang ZhouDepartment of Otolaryngology Head Neck Surgery, Tianjin Medical University General Hospital, Tianjin, China.
Jianjun ChenDepartment of Otorhinolaryngology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei Province, China.
Qingquan HuaDepartment of Otorhinolaryngology Head and Neck Surgery, Renmin Hospital of Wuhan University, Wuhan, Hubei Province, China.
Ling ZhouDepartment of Otorhinolaryngology, The First Affiliated Hospital of Heilongjiang University of Chinese Medicine, Haerbin, Heilongjiang Province, China.
Xiaobing ZhangDepartment of Otorhinolaryngology Head and Neck Surgery, The First Hospital of Lanzhou University, Lanzhou, Gansu Province, China.
Xiong ChenDepartment of Otorhinolaryngology Head and Neck Surgery, Zhongnan Hospital of Wuhan University, Wuhan, Hubei Province, China.
Chao LiDepartment of Otorhinolaryngology, The Second Hospital of Tianjin Medical University, Tianjin, China.
Ruixia MaDepartment of Otorhinolaryngology Head and Neck Surgery, The First People's Hospital of Yinchuan, Yinchuan, Ningxia Hui Autonomous Region, China.
Hua ZhangDepartment of Otolaryngology, The First Hospital of Xinjiang Medical University, Urumqi, Xinjiang Uygur Autonomous Region, China.
Zhendong XuDepartment of Otolaryngology, Baotou Central Hospital, Baotou, Inner Mongolia Autonomous Region, China.
Mei HanDepartment of Otolaryngology, The Affiliated Hospital of Changchun University of Chinese Medicine, Changchun, Jilin Province, China.
Xiangdong WangDepartment of Otorhinolaryngology Head and Neck Surgery, Beijing Tongren Hospital, Capital Medical University, Beijing, China.
Luo ZhangDepartment of Otorhinolaryngology Head and Neck Surgery, Beijing Tongren Hospital, Capital Medical University, Beijing, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Patients with moderate-to-severe allergic rhinitis (AR) often experience a heavy clinical burden and require more medications to alleviate nasal symptoms. The aim of this study was to evaluate the efficacy and safety of GSP301, a fixed-dose combination nasal spray containing olopatadine hydrochloride and mometasone furoate, in patients with seasonal AR (SAR). Methods: In this multicenter, randomized, double-blind, parallel-group study, moderate-to-severe SAR patients were assigned at a 1:1:1 ratio to receive intranasal GSP301, olopatadine hydrochloride (OLO), or mometasone furoate (MF) for 14 days. The primary endpoint was the change from baseline in the average A.M. and P.M. 12-hour reflective total nasal symptom score (rTNSS). Secondary endpoints included changes in the instantaneous TNSS (iTNSS), individual nasal symptoms, reflective total ocular symptom score (rTOSS), instantaneous total ocular symptom score (iTOSS), individual ocular symptoms, and rhinoconjunctivitis quality-of-life questionnaire (RQLQ). Exploratory endpoints and adverse events were also analyzed. Results: Among the 534 subjects, the GSP301 group demonstrated statistically significant improvements in the average rTNSS compared with the OLO group [posterior least square mean difference (LSMD) = -0.56; Conclusion: Compared with OLO and MF, GSP301 demonstrated superior efficacy, safety, and potential advantages in alleviating local inflammation in patients with moderate-to-severe SAR.

Indexed as

GSP301Mometasone furoateOlopatadine hydrochlorideSeasonal allergic rhinitis

Identifiers

PMID41732343
PMCPMC12925058

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.